This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
A Second look at the early stage data of FTX-6058 in treating sickle-cell disease
Ticker(s): FULCWho's the expert?
Institution: University of Miami
- Board Certified hematologist, in practice for 17 years
- Currently working in a hemophilia center where he sees patients for many hematologic malignancies including hemophilia B and sickle cell disease.
Interview GoalDiscussing the existing phase 1 data for FTX 6058, an oral EED-targeting PRC2 inhibitor in development by Fulcrum Therapeutics, inclusive of the recent data presented at EHA on FTX-6058 in treating SCD?
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
